The Health and Human Services Office of Inspector General has found that, in a few cases, FDA officials veered from the accelerated approval pathway.
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...
The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...
The Associated Press on MSN12d
FDA approves painkiller designed to eliminate risks of addiction associated with opioidsThe U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback